CardioSource WorldNews - Page 13

Helping hospitals and practices measure and improve the quality of care they provide .
Data Animal Data ENTRESTO treatment during organogenesis resulted in increased embryo-fetal lethality in rats at doses ≥ 49 mg sacubitril / 51 mg valsartan / kg / day ( ≤ 0.14 [ LBQ657 , the active metabolite ] and 1.5 [ valsartan ] - fold the maximum recommended human dose [ MRHD ] of 97 / 103 mg twice-daily on the basis of the area under the plasma drug concentration-time curve [ AUC ]) and rabbits at doses ≥ 5 mg sacubitril / 5 mg valsartan / kg / day ( 4-fold and 0.06-fold the MRHD on the basis of valsartan and LBQ657 AUC , respectively ). ENTRESTO is teratogenic based on a low incidence of fetal hydrocephaly , associated with maternally toxic doses , which was observed in rabbits at an ENTRESTO dose of ≥ 5 mg sacubitril / 5 mg valsartan / kg / day . The adverse embryo-fetal effects of ENTRESTO are attributed to the angiotensin receptor antagonist activity .
Pre- and postnatal development studies in rats at sacubitril doses up to 750 mg / kg / day ( 4.5-fold the MRHD on the basis of LBQ657 AUC ) and valsartan at doses up to 600 mg / kg / day ( 0.86-fold the MRHD on the basis of AUC ) indicate that treatment with ENTRESTO during organogenesis , gestation and lactation may affect pup development and survival .
8.2 Lactation Risk Summary There is no information regarding the presence of sacubitril / valsartan in human milk , the effects on the breastfed infant , or the effects on milk production . Sacubitril / valsartan is present in rat milk . Because of the potential for serious adverse reactions in breastfed infants from exposure to sacubitril / valsartan , advise a nursing woman that breastfeeding is not recommended during treatment with ENTRESTO .
Data Following an oral dose ( 15 mg sacubitril / 15 mg valsartan / kg ) of [ 14 C ] ENTRESTO to lactating rats , transfer of LBQ657 into milk was observed . After a single oral administration of 3 mg / kg [ 14 C ] valsartan to lactating rats , transfer of valsartan into milk was observed .
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established .
8.5 Geriatric Use No relevant pharmacokinetic differences have been observed in elderly ( ≥65 years ) or very elderly ( ≥75 years ) patients compared to the overall population [ see Clinical Pharmacology ( 12.3 ) in the full prescribing information ].
8.6 Hepatic Impairment No dose adjustment is required when administering ENTRESTO to patients with mild hepatic impairment ( Child-Pugh A classification ). The recommended starting dose in patients with moderate hepatic impairment ( Child-Pugh B classification ) is 24 / 26 mg twice daily . The use of ENTRESTO in patients with severe hepatic impairment ( Child-Pugh C classification ) is not recommended , as no studies have been conducted in these patients [ see Dosage and Administration ( 2.4 ) in the full prescribing information , Clinical Pharmacology ( 12.3 ) in the full prescribing information ].
8.7 Renal Impairment No dose adjustment is required in patients with mild ( eGFR 60 to 90 mL / min / 1.73 m 2 ) to moderate ( eGFR 30 to 60 mL / min / 1.73 m 2 ) renal impairment . The recommended starting dose in patients with severe renal impairment ( eGFR < 30 mL / min / 1.73 m 2 ) is 24 / 26 mg twice daily [ see Dosage and Administration ( 2.3 ) in the full prescribing information , Warnings and Precautions ( 5.4 ) and Clinical Pharmacology ( 12.3 ) in the full prescribing information ].
10 OVERDOSAGE Limited data are available with regard to overdosage in human subjects with ENTRESTO . In healthy volunteers , a single dose of ENTRESTO 583 mg sacubitril / 617 mg valsartan , and multiple doses of 437 mg sacubitril / 463 mg valsartan ( 14 days ) have been studied and were well tolerated .
Hypotension is the most likely result of overdosage due to the blood pressure lowering effects of ENTRESTO . Symptomatic treatment should be provided .
ENTRESTO is unlikely to be removed by hemodialysis because of high protein binding .
Distributed by : Novartis Pharmaceuticals Corporation East Hanover , New Jersey 07936
© Novartis T2015-100 ENTRESTO is a trademark of Novartis AG
Issued : July / 2015
Helping hospitals and practices measure and improve the quality of care they provide .

· ACTION Registry ® – GWTG

· AFib Ablation Registry

· CathPCI Registry ®

· Diabetes Collaborative Registry ®

· ICD Registry

· IMPACT Registry ®

· LAAO Registry

· PINNACLE Registry ®

· PVI Registry

· STS / ACC TVT Registry CVQuality . ACC . org / NCDR

© 2016 , American College of Cardiology N1693
B:10.75” T:10.5” S:9.5” 8.6 Hepatic Impairment No dose adjustment is required when administering ENTRESTO to patients with mild hepatic impairment (Child-Pugh A classification). The recommended starting dose in patients with moderate hepatic impairment (Child-Pugh B classification) is 24/26 mg twice daily. The use of ENTRESTO in patients with severe hepatic impairment (Child-Pugh C classification) is not recomm VFVB27GVFW2fR&VV6GV7FVBFW6RFVG26VRF6vRBF֖7G&F"BFRgV&W67&&rf&F6Ɩ6&6w"2FRgV&W67&&rf&FࠤFFFFTE$U5DG&VFVBGW&r&vvVW62&W7VFVB7&V6VBV''fWFWFƗG&G2BF6W0(RCr67V&G&Srf6'FrF(BB%cSrFR7FfRWF&ƗFUBRf6'FfBFRV&V6VFVBVF6R$Ebr2rGv6RFǒFR&62bFR&VVFW"FR6G'Vr66VG&FFR7W'fRT5ҒB&&&G2BF6W2(RRr67V&G&Rpf6'FrFBfBBbfBFR$BFR&62bf6'FB%cSrT2&W7V7FfVǒTE$U5D2FW&FvV2&6VBr6FV6RbfWFG&6Wǒ766FVBvFFW&ǒF2F6W2v6v2'6W'fVB&&&G2BTE$U5DF6Rb(RRr67V&G&Rpf6'FrFFRGfW'6RV''fWFVffV7G2bTE$U5D&RGG&'WFVBFFRvFV6&V6WF"Fv7B7FfG&RB7FFFWfVVB7GVFW2&G2B67V&G&F6W2WFsSrrFBRfBFP$BFR&62b%cSrT2Bf6'FBF6W2WFcrrFbfBFR$@FR&62bT2F6FRFBG&VFVBvFTE$U5DGW&r&vvVW62vW7FFB7FFffV7BWFWfVVBB7W'ffࣂ"7FF&67V'FW&R2f&F&Vv&FrFR&W6V6Rb67V&G&f6'FV֖ƲFRVffV7G2FP'&V7FfVBfB"FRVffV7G2֖Ʋ&GV7F67V&G&f6'F2&W6VB&B֖Ʋ&V6W6R`FRFVFf"6W&W2GfW'6R&V7F2'&V7FfVBfG2g&W7W&RF67V&G&f6'FGf6PW'6rvFB'&V7FfVVFr2B&V6VFVBGW&rG&VFVBvFTE$U5DFFfvr&F6RRr67V&G&Rrf6'FrbD5TE$U5DF7FFr&G2G&6fW"b%cSrF֖Ʋv2'6W'fVBgFW"6vR&F֖7G&Fb2rrD5f6'FF7FFr&G2G&6fW"bf6'FF֖Ʋv2'6W'fVBࣂBVFG&2W6P6fWGBVffV7FfVW72VFG&2FVG2fRB&VVW7F&Ɨ6VBࠣr&V&V@F6RFW7FVB2&WV&VBFVG2vF֖BTte"cF֖s2"FFW&FPTte"3Fc֖s2"&V&VBFR&V6VFVB7F'FrF6RFVG2vF6WfW&R&V&VBTte"3֖s2"2#B#brGv6RFǒ6VRF6vRBF֖7G&F"2FRgV&W67&&rf&Fv&w2B&V6WF2RBB6Ɩ6&6w"2FRgV&W67&&rf&FdU$D4tPƖ֗FVBFF&Rf&RvF&Vv&BFfW&F6vRV7V&V7G2vFTE$U5DVFfVFVW'26vRF6RbTE$U5DS2r67V&G&crrf6'FBVFRF6W2bC3rp67V&G&Cc2rf6'FBF2fR&VV7GVFVBBvW&RvVFW&FVBइFV62FR7BƖVǒ&W7VBbfW&F6vRGVRFFR&B&W77W&RvW&rVffV7G2`TE$U5D7FF2G&VFVB6VB&R&fFVBTE$U5D2VƖVǒF&R&VfVB'VFǗ62&V6W6Rbv&FV&FrF7G&'WFVB'f'F2&6WWF626'&FV7BfW"WrW'6Ws3`*f'F0C#RTE$U5D2G&FV&bf'F2p77VVCVǒ#PRvW&G&2W6P&VWfB&6WF2FffW&V6W2fR&VV'6W'fVBVFW&ǒ(ScRV'2"fW'VFW&ǐ(SsRV'2FVG26&VBFFRfW&VF6VR6Ɩ6&6w"2FRgV&W67&&rf&Fࠣ33CSe%5uF&EEFB $U$TB%d4 "333CS`6ƖVCf'F0&GV7C5c`6FSUE"3SS`FFS6WFV&W"r#RSC2Х&c&B㠤"w&B3C`6#D0f6SƗfSR"RR G&ӢR"bR &VVCsR"bsR fG3&6W'fRVfWF66FV6V@C2&S'6G&ff37W'&P3vV'F7C7V6V6e"7V6V6F&U&W73f'F35cc$e533CSc33CSe%5uF&EEVr7F2CD7&7F6W2V7W&R@F&B6vRvR67VW"'&Vb7V'&fRFRVƗGb6&RFW&fFRࠬ+p+p+p+p+p5D&Vv7G'*( 2uuD~(J f"&F&Vv7G'(J 6F4&Vv7G'*F&WFW26&&FfR&Vv7G'*औ4B&Vv7G'(J +p+p+p+p+p5B&Vv7G'*&Vv7G'(J 4R&Vv7G'*d&Vv7G'(J 5E242EeB&Vv7G'(J 5eVƗG42&r4E *#bW&66VvRb6&Fwc0rRSCBР